Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel-Reference-Cited by-同舟云学术

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel

Published:2012-10-30 Issue:10 Volume:7 Page:e48186
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kawahara Takashi,Miyoshi Yasuhide,Sekiguchi Zenkichi,Sano Futoshi,Hayashi Narihiko,Teranishi Jun-ichi,Misaki Hiroshi,Noguchi Kazumi,Kubota Yoshinobu,Uemura Hiroji

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference16 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;IF Tannock;N Engl J Med,2004

2. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy;MR Cooperberg;J Clin Oncol,2009

3. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate;C Huggins;CA Cancer J Clin,1972

4. Chemotherapy of advanced prostatic carcinoma;RE Millikan;Semin Oncol,1999

5. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer;J Tabernero;Ann Oncol,2004

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients;Scientific Reports;2023-02-15

2. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer;Prostate International;2022-03

3. Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study;BioMed Research International;2020-07-02

4. The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer;BioMed Research International;2019-10-31

5. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands;Clinical Genitourinary Cancer;2019-10